Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US

Liao, Cheng-I; Chow, Stephanie; Chen, Lee-may; Kapp, Daniel S.; Mann, Amandeep; Chan, John K.

doi:10.1016/j.ygyno.2018.01.030

Cited by 43 publications

(37 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Future trends will be similarly impacted by advances in the understanding of ovarian cancer biology. For instance, because many epithelial cancers are now recognized to originate in the fallopian tubes, high‐grade serous carcinoma is increasingly being classified as cancer of the fallopian tube rather than of the ovary, although the accuracy thereof requires further research.…”

Section: Ovarian Cancer Subtypesmentioning

confidence: 99%

Ovarian cancer statistics, 2018

Torre

Trabert

DeSantis

et al. 2018

CA A Cancer J Clinicians

2,677

2,126

View full text Add to dashboard Cite

In 2018, there will be approximately 22,240 new cases of ovarian cancer diagnosed and 14,070 ovarian cancer deaths in the United States. Herein, the American Cancer Society provides an overview of ovarian cancer occurrence based on incidence data from nationwide population-based cancer registries and mortality data from the National Center for Health Statistics. The status of early detection strategies is also reviewed. In the United States, the overall ovarian cancer incidence rate declined from 1985 (16.6 per 100,000) to 2014 (11.8 per 100,000) by 29% and the mortality rate declined between 1976 (10.0 per 100,000) and 2015 (6.7 per 100,000) by 33%. Ovarian cancer encompasses a heterogenous group of malignancies that vary in etiology, molecular biology, and numerous other characteristics. Ninety percent of ovarian cancers are epithelial, the most common being serous carcinoma, for which incidence is highest in non-Hispanic whites (NHWs) (5.2 per 100,000) and lowest in non-Hispanic blacks (NHBs) and Asians/Pacific Islanders (APIs) (3.4 per 100,000). Notably, however, APIs have the highest incidence of endometrioid and clear cell carcinomas, which occur at younger ages and help explain comparable epithelial cancer incidence for APIs and NHWs younger than 55 years. Most serous carcinomas are diagnosed at stage III (51%) or IV (29%), for which the 5-year cause-specific survival for patients diagnosed during 2007 through 2013 was 42% and 26%, respectively. For all stages of epithelial cancer combined, 5-year survival is highest in APIs (57%) and lowest in NHBs (35%), who have the lowest survival for almost every stage of diagnosis across cancer subtypes. Moreover, survival has plateaued in NHBs for decades despite increasing in NHWs, from 40% for cases diagnosed during 1992 through 1994 to 47% during 2007 through 2013. Progress in reducing ovarian cancer incidence and mortality can be accelerated by reducing racial disparities and furthering knowledge of etiology and tumorigenesis to facilitate strategies for prevention and early detection. CA Cancer J Clin 2018;68:284-296. © 2018 American Cancer Society.

show abstract

Section: Ovarian Cancer Subtypesmentioning

confidence: 99%

Ovarian cancer statistics, 2018

Torre

Trabert

DeSantis

et al. 2018

CA A Cancer J Clinicians

2,677

2,126

View full text Add to dashboard Cite

show abstract

“…Over the past decades, cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has drastically changed the approach to patients with peritoneal surface malignancies (PSM) and improved prognosis for appendiceal, colorectal, and ovarian tumors, as well as peritoneal mesotheliomas 1‐6 . While the incidence continues to increase, access to PSM experts remains limited, with many CRS/HIPEC centers located in academic institutions due to its inherent complexity and investigational nature for some primaries 7‐9 . This leads to insufficient referrals of patients who desperately need treatment 10 …”

Section: Introductionmentioning

confidence: 99%

Surgical and oncological outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a nonacademic center: 25‐year experience

Nikiforchin

Gushchin

King

et al. 2021

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is predominantly performed and studied in academic centers. While developing CRS/HIPEC programs in nonacademic hospitals can increase accessibility, its safety and oncological efficacy remains unclear. We evaluated CRS/HIPEC outcomes in a nonacademic setting. Methods A single‐center descriptive study was conducted using a prospective database. Data of all CRS/HIPEC attempts in peritoneal surface malignancies (PSM) patients from October 1994 to November 2019 were extracted. Surgical and survival outcomes were measured. Center experience was assessed by quartiles of cases. Results Overall, 856 patients underwent 948 CRS/HIPEC attempts: 788 (83%) completed CRS/HIPECs, 144 (15%) aborted HIPECs, and 16 (2%) complete cytoreductions (CC‐0/1) without chemoperfusion. For completed CRS/HIPECs, median peritoneal cancer index was 24 (interquartile range: 10–33) and CC‐0/1 rate was 88%. Major complications occurred in 23.5% with 30‐ and 100‐day mortality of 1.0% and 2.3%, respectively. Median overall survival was 68 months (95% confidence interval [CI]: 50–86). Median progression‐free survival was 37 months (95%CI: 28–46). Incomplete cytoreduction and major complication rates decreased over time, while mortality remained low and constant. Conclusions CRS/HIPEC at a nonacademic center with advanced surgical and auxiliary services is a safe option to treat PSM with favorable surgical and oncological outcomes.

show abstract

“…Epithelial, fallopian tube and peritoneal cancer While these cancers often occur after the menopause, they also affect a significant number of premenopausal women 43–45…”

Section: Introductionmentioning

confidence: 99%

European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis

Rees

Angioli

Coleman

et al. 2020

Int J Gynecol Cancer

View full text Add to dashboard Cite

Worldwide, it is estimated that about 1.3 million new gynecological cancer cases are diagnosed each year. For 2018, the predicted annual totals were cervix uteri 569 847, corpus uteri 382 069, ovary 295 414, vulva 44 235, and vagina 17 600. Treatments include hysterectomy with or without bilateral salpingo-oophorectomy, radiotherapy, and chemotherapy. These can result in loss of ovarian function and, in women under the age of 45 years, early menopause. The aim of this position statement is to set out an individualized approach to the management, with or without menopausal hormone therapy, of menopausal symptoms and the prevention and treatment of osteoporosis in women with gynecological cancer. Our methods comprised a literature review and consensus of expert opinion. The limited data suggest that women with low-grade, early-stage endometrial cancer may consider systemic or topical estrogens. However, menopausal hormone therapy may stimulate tumor growth in patients with more advanced disease, and non-hormonal approaches are recommended. Uterine sarcomas may be hormone dependent, and therefore estrogen and progesterone receptor testing should be undertaken to guide decisions as to whether menopausal hormone therapy or non-hormonal strategies should be used. The limited evidence available suggests that menopausal hormone therapy, either systemic or topical, does not appear to be associated with harm and does not decrease overall or disease-free survival in women with non-serous epithelial ovarian cancer and germ cell tumors. Caution is required with both systemic and topical menopausal hormone therapy in women with serous and granulosa cell tumors because of their hormone dependence, and non-hormonal options are recommended as initial therapy. There is no evidence to contraindicate the use of systemic or topical menopausal hormone therapy by women with cervical, vaginal, or vulvar cancer, as these tumors are not considered to be hormone dependent.

show abstract

Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US

Cited by 43 publications

References 27 publications

Ovarian cancer statistics, 2018

Ovarian cancer statistics, 2018

Surgical and oncological outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a nonacademic center: 25‐year experience

European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis

Contact Info

Product

Resources

About